Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC.

about

Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC.

Item

http://www.wikidata.org/entity/Q47943403

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Phase IB Trial of the Anti-Can ...... Metastatic Non-Squamous NSCLC.

@en

Phase IB Trial of the Anti-Can ...... Metastatic Non-Squamous NSCLC.

@nl

type

Item

label

Phase IB Trial of the Anti-Can ...... Metastatic Non-Squamous NSCLC.

@en

Phase IB Trial of the Anti-Can ...... Metastatic Non-Squamous NSCLC.

@nl

prefLabel

Phase IB Trial of the Anti-Can ...... Metastatic Non-Squamous NSCLC.

@en

Phase IB Trial of the Anti-Can ...... Metastatic Non-Squamous NSCLC.

@nl

P1476

Phase IB Trial of the Anti-Can ...... Metastatic Non-Squamous NSCLC.

@en

P2093

Ann M Kapoun

http://www.w3.org/2001/XMLSchema#string

Ben Markman

http://www.w3.org/2001/XMLSchema#string

Brett G M Hughes

http://www.w3.org/2001/XMLSchema#string

Dean L Harris

http://www.w3.org/2001/XMLSchema#string

Dusan Kotasek

http://www.w3.org/2001/XMLSchema#string

Lu Xu

http://www.w3.org/2001/XMLSchema#string

Manuel Hidalgo

http://www.w3.org/2001/XMLSchema#string

Mark J McKeage

http://www.w3.org/2001/XMLSchema#string

Michael B Jameson

http://www.w3.org/2001/XMLSchema#string

Michael J Millward

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis

Tumour stem cells and drug resistance

Screening for epidermal growth factor receptor mutations in lung cancer

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee

Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis.

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors.

P2888

s11523-017-0543-0

P31

scholarly article

P356

10.1007/S11523-017-0543-0

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29188408

http://www.w3.org/2001/XMLSchema#string